JP2018505199A5 - - Google Patents

Download PDF

Info

Publication number
JP2018505199A5
JP2018505199A5 JP2017542048A JP2017542048A JP2018505199A5 JP 2018505199 A5 JP2018505199 A5 JP 2018505199A5 JP 2017542048 A JP2017542048 A JP 2017542048A JP 2017542048 A JP2017542048 A JP 2017542048A JP 2018505199 A5 JP2018505199 A5 JP 2018505199A5
Authority
JP
Japan
Prior art keywords
solvate
crystalline
accordance
data substantially
diffraction data
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017542048A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018505199A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/050755 external-priority patent/WO2016128936A1/en
Publication of JP2018505199A publication Critical patent/JP2018505199A/ja
Publication of JP2018505199A5 publication Critical patent/JP2018505199A5/ja
Pending legal-status Critical Current

Links

JP2017542048A 2015-02-13 2016-02-12 (S)−5−ベンジル−N−(5−メチル−4−オキソ−2,3,4,5テトラヒドロベンゾ[b][1,4]オキサゼピン−3−イル)−4H−1,2,4−トリアゾール−3−カルボキサミドの結晶形 Pending JP2018505199A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562115674P 2015-02-13 2015-02-13
US62/115,674 2015-02-13
PCT/IB2016/050755 WO2016128936A1 (en) 2015-02-13 2016-02-12 Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide

Publications (2)

Publication Number Publication Date
JP2018505199A JP2018505199A (ja) 2018-02-22
JP2018505199A5 true JP2018505199A5 (enExample) 2019-03-22

Family

ID=55359562

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017542048A Pending JP2018505199A (ja) 2015-02-13 2016-02-12 (S)−5−ベンジル−N−(5−メチル−4−オキソ−2,3,4,5テトラヒドロベンゾ[b][1,4]オキサゼピン−3−イル)−4H−1,2,4−トリアゾール−3−カルボキサミドの結晶形

Country Status (11)

Country Link
US (1) US10287280B2 (enExample)
EP (1) EP3256467A1 (enExample)
JP (1) JP2018505199A (enExample)
KR (1) KR20170117472A (enExample)
CN (1) CN107207485A (enExample)
AU (1) AU2016217496B2 (enExample)
BR (1) BR112017017411A2 (enExample)
CA (1) CA2976172A1 (enExample)
IL (1) IL253731A0 (enExample)
RU (1) RU2017131862A (enExample)
WO (1) WO2016128936A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6754772B2 (ja) 2015-10-23 2020-09-16 武田薬品工業株式会社 複素環化合物
SG10201913587WA (en) 2016-02-05 2020-02-27 Denali Therapeutics Inc Inhibitors of receptor-interacting protein kinase 1
DK3552017T3 (da) 2016-12-09 2022-05-16 Denali Therapeutics Inc Forbindelser, der er anvendelige som ripk1-inhibitorer
WO2019123219A1 (en) * 2017-12-20 2019-06-27 Glaxosmithkline Intellectual Property Development Limited Crystalline salt form of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide
PT3788044T (pt) 2018-05-03 2023-08-31 Rigel Pharmaceuticals Inc Compostos inibidores de rip1 e métodos para preparar e usar os mesmos
KR102823195B1 (ko) 2018-05-03 2025-06-20 리겔 파마슈티칼스, 인크. Rip1 억제 화합물 및 이를 제조하고 사용하는 방법
US20220218719A1 (en) * 2019-05-17 2022-07-14 Glaxosmithkline Intellectual Property Development Limited Matrix composition comprising (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide
EP4025574B1 (en) 2019-09-06 2025-05-07 Rigel Pharmaceuticals, Inc. Rip1 inhibitory compounds and methods for making and using the same
CR20220075A (es) 2019-09-06 2022-07-14 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos
CN115298184B (zh) 2019-11-07 2025-01-28 里格尔药品股份有限公司 杂环rip1抑制化合物
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
AR122703A1 (es) 2020-07-01 2022-09-28 Rigel Pharmaceuticals Inc Inhibidores de rip1k
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
WO2023137035A1 (en) 2022-01-12 2023-07-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI648273B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類(三)

Similar Documents

Publication Publication Date Title
RU2017131862A (ru) КРИСТАЛЛИЧЕСКИЕ ФОРМЫ (S)-5-БЕНЗИЛ-N-(5-МЕТИЛ-4-ОКСО-2,3,4,5-ТЕТРАГИДРОБЕНЗО[b][1,4]ОКСАЗЕПИН-3-ИЛ)-4H-1,2,4-ТРИАЗОЛ-3-КАРБОКСАМИДА
HRP20210748T1 (hr) Postupak priprave spojeva s aktivnošću inhibitora hiv integraze
JP2018024682A5 (enExample)
CN112566907A (zh) 作为ret抑制剂的吡唑衍生物
JP2022078315A5 (enExample)
JP2011510079A5 (enExample)
JP2008019161A5 (enExample)
RU2010145171A (ru) Аналоги галихондрина в
JP2018521020A5 (enExample)
JP2014063186A5 (enExample)
JP2012531408A5 (enExample)
JP2013532130A5 (enExample)
CN114206850A (zh) 作为crac抑制剂的2h-苯并吡喃衍生物
JP2025111617A5 (enExample)
JP2015506987A5 (enExample)
RU2016118796A (ru) Новая кристаллическая форма 2-{ 3-[2-(1-{ [3, 5-бис(дифторметил)-1н-пиразол-1-ил]ацетил} пиперидин-4-ил)-1, 3-тиазол-4-ил]-4, 5-дигидро-1, 2-оксазол-5-ил} -3-хлорфенилметансульфоната
JP2012508747A5 (enExample)
JP2010507590A5 (enExample)
JP2023508938A5 (enExample)
JP2015038184A5 (enExample)
JP2015042663A5 (enExample)
AR081659A1 (es) Procedimiento de obtencion de la forma cristalina ii del febuxostat
JP2016510767A5 (enExample)
JP2018009003A5 (enExample)
JP2016539994A5 (enExample)